Recent Quotes (30 days)

You have no recent quotes
chg | %

Shire PLC news

   Watch this stock
Showing stories 1 - 10 of about 111   

Articles published

SHP 4,007.66 +112.66 (2.89%)
price chart
AbbVie says $55 billion acquisition of Shire officially dead
(Reuters) - U.S. drugmaker AbbVie Inc (ABBV.N) said on Monday it has reached agreement with Shire Plc (SHP.L) to officially call off its proposed $55 billion purchase of the Irish company, and will pay Shire a $1.64 billion breakup fee for walking away ...
Panmure Gordon Upgrades Shire PLC to Buy (SHPG)  sleekmoney
Related articles »  
Shire PLC Takes a Dive as AbbVie Reconsiders Offer
Billionaire stock picks Paramount Gold and Silver Corp. (NYSEMKT:PZG), Nanosphere, Inc. (NASDAQ:NSPH) and Orexigen Therapeutics, Inc. (NASDAQ:OREX) have made noteworthy climbs on the market this Wednesday.
Buy Shire PLC (ADR)(NASDAQ:SHPG) on Weakness: CRT Capital  Street Newswire (registration)
CRT Capital Upgrades Shire PLC to Buy (SHPG)  Mideast Time
Related articles »  
Shire plc (SHPG) Tops Q3 EPS Views; Boosts FY14 EPS Outlook
Shire plc (NASDAQ: SHPG) reported Q3 EPS of $2.93, $0.46 better than the analyst estimate of $2.47. Revenue for the quarter came in at $1.55 billion versus the consensus estimate of $1.46 billion.
Shire's Got Big Plans for AbbVie's Breakup Fee  Wall Street Journal (blog)
AbbVie head criticizes Canada's patent laws on drugs  The Globe and Mail
Related articles »  
Why Shire plc (ADR) Is Today's Worst Biotech Stock
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis.
AbbVie's Threat on Shire Deal Is Latest Tax Rule Fallout  Bloomberg
$54 billion AbbVie-Shire deal appears to be dying
Related articles »  
Big Movers: Shire PLC (ADR) (NASDAQ:SHPG), Myriad Genetics, Inc. (NASDAQ ...
Shire PLC (ADR) (NASDAQ:SHPG) reported Q3 earnings and sales that exceeded analysts' expectations. SHPG is trading around the mid-point of the 52-week range between $121.57 and $264.98.
Why Shire PLC, Hikma Pharmaceuticals Plc And BTG plc Could Complement ...
Investor sentiment in the pharmaceutical sector has weakened considerably in recent days after AbbVie decided to ditch its bid for Shire (LSE: SHP) (NASDAQ: SHPG.US). The reason for it is a closing of a loophole that allowed US companies to relocate ...
Related articles »  
Shire PLC Stock Price Up 5.2% on Better-Than-Expected Earnings (SHPG)
Shire PLC logo Shire PLC (NASDAQ:SHPG)'s share price rose 5.2% on Friday following a better than expected earnings announcement, Analyst Ratings Network reports.
Shire PLC Given Average Rating of "Buy" by Analysts (NASDAQ:SHPG)  Ticker Report
Shire PLC (SHPG) Releases Quarterly Earnings Results, Beats Estimates By ...  WKRB News
Related articles »  
Allergan Might Approach Shire For Acquisition
Paulson & Co, which had a 2% stake in Allergan Inc (AGN) as of June 30, pressed the pharma giant today to consider an acquisition deal with Shire PLC (ADR) (SHPG). Paulson owns 4.4% of Shire's stock as of October 17. Allergan's CEO David Pyott ...
Top Allergan holder Paulson urges deal with Shire: sources  Reuters UK
Paulson Urges Allergan/Shire Tie-up  Wall Street Journal (blog)
Related articles »  
Shire PLC Now Covered by Analysts at Deutsche Bank (SHPG)
Deutsche Bank began coverage on shares of Shire PLC (NASDAQ:SHPG) in a research note issued to investors on Tuesday. The firm issued a buy rating and a $220.00 price target on the stock.
Shire PLC Given Average Recommendation of �Buy� by Analysts (NASDAQ:SHPG)  WKRB News
Shire PLC Earns Buy Rating from Analysts at Deutsche Bank (SHPG)  Mideast Time
Related articles »  
Why I'd Still Buy AstraZeneca plc Despite Shire PLC Deal Collapse
2014 has been a superb year for investors in AstraZeneca (LSE: AZN). That's because shares in the pharmaceutical company have risen by 19% since the start of the year, which is well ahead of the FTSE 100′s disappointing decline of 6%.
Related articles »